Literature DB >> 20709440

Treating profound hyponatremia: a strategy for controlled correction.

Richard H Sterns1, John Kevin Hix, Stephen Silver.   

Abstract

An alcoholic patient presented with profound hyponatremia (serum sodium concentration, 96 mEq/L) caused by the combined effects of a thiazide diuretic, serotonin reuptake inhibitor, beer potomania, and hypovolemia. A computed tomographic scan of the brain was indistinguishable from one obtained 3 weeks earlier when he was normonatremic. Concurrent administration of 3% saline solution and desmopressin controlled the rate of correction to an average of 6 mEq/L daily and resulted in full neurologic recovery without evidence of osmotic demyelination. This case illustrates the value of controlled correction of profound hyponatremia.
Copyright © 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709440     DOI: 10.1053/j.ajkd.2010.04.020

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  21 in total

1.  [Language of the other].

Authors:  L von Ferber
Journal:  Fortschr Med       Date:  1975-12-04

2.  Emergency Neurological Life Support: Acute Non-traumatic Weakness.

Authors:  Anna Finley Caulfield; Oliver Flower; Jose A Pineda; Shahana Uddin
Journal:  Neurocrit Care       Date:  2017-09       Impact factor: 3.210

3.  Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM).

Authors:  E Sbardella; A M Isidori; G Arnaldi; M Arosio; C Barone; A Benso; R Berardi; G Capasso; M Caprio; F Ceccato; G Corona; S Della Casa; L De Nicola; M Faustini-Fustini; E Fiaccadori; L Gesualdo; S Gori; A Lania; G Mantovani; P Menè; G Parenti; C Pinto; R Pivonello; P Razzore; G Regolisti; C Scaroni; F Trepiccione; A Lenzi; A Peri
Journal:  J Endocrinol Invest       Date:  2017-11-20       Impact factor: 4.256

Review 4.  Treatment of Severe Hyponatremia.

Authors:  Richard H Sterns
Journal:  Clin J Am Soc Nephrol       Date:  2018-01-02       Impact factor: 8.237

5.  [Hyponatremia and tolvaptan : what is the situation 5 years after approval?].

Authors:  J Hensen
Journal:  Internist (Berl)       Date:  2015-07       Impact factor: 0.743

6.  Risk Factors and Outcomes of Rapid Correction of Severe Hyponatremia.

Authors:  Jason C George; Waleed Zafar; Ion Dan Bucaloiu; Alex R Chang
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-05       Impact factor: 8.237

7.  Hyponatremia: vasopressin antagonists in hyponatremia: more data needed.

Authors:  Richard Sterns; John Hix
Journal:  Nat Rev Nephrol       Date:  2010-12-14       Impact factor: 28.314

Review 8.  [Treatment of hyponatremia: role of vaptans].

Authors:  J Hensen
Journal:  Internist (Berl)       Date:  2010-12       Impact factor: 0.743

Review 9.  [Hyponatremia : The water-intolerant patient].

Authors:  J Hensen
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-08-23       Impact factor: 0.840

Review 10.  Hyponatremia: pathophysiology, classification, manifestations and management.

Authors:  Helbert Rondon-Berrios; Emmanuel I Agaba; Antonios H Tzamaloukas
Journal:  Int Urol Nephrol       Date:  2014-09-24       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.